Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Christine Ring Biography and Net Worth

General Counsel of Nurix Therapeutics

Christine Ring, Ph.D., J.D., has served as Secretary of Nurix since March 2020 and as the company’s General Counsel since September 2019. Prior to joining Nurix, Dr. Ring held multiple positions assisting companies protect intellectual property, engage in licensing transactions, raise capital, and transition from private companies into public companies. Her most recent corporate positions were as Senior Vice President, Legal at Dermira, Inc., a biotechnology company focused on medical dermatology, and as Senior Vice President of Technology, Strategy & Licensing at Amyris, Inc., a biotechnology company focused on renewable fuels and specialty chemicals. Dr. Ring holds an A.B. in Biophysics from the University of California, Berkeley, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and a J.D. from the University of California, Hastings College of the Law.

What is Christine Ring's net worth?: The estimated net worth of Christine Ring is at least $561,927.20 as of October 14th, 2024. Dr. Ring owns 24,592 shares of Nurix Therapeutics stock worth more than $561,927 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Ring may own. Additionally, Dr. Ring receives an annual salary of $595,830.00 as General Counsel at Nurix Therapeutics. Learn More about Christine Ring's net worth.
How old is Christine Ring?: Dr. Ring is currently 59 years old. There are 4 older executives and no younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who is 62 years old. Learn More on Christine Ring's age.
What is Christine Ring's salary?: As the General Counsel of Nurix Therapeutics, Inc., Dr. Ring earns $595,830.00 per year. There are 3 executives that earn more than Dr. Ring. The highest earning executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who commands a salary of $986,320.00 per year. Learn More on Christine Ring's salary.
How do I contact Christine Ring?: The corporate mailing address for Dr. Ring and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at [email protected]. Learn More on Christine Ring's contact information.
Has Christine Ring been buying or selling shares of Nurix Therapeutics?: During the last quarter, Christine Ring has sold $210,294.80 in Nurix Therapeutics stock. Most recently, Christine Ring sold 3,290 shares of the business's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $25.00, for a transaction totalling $82,250.00. Following the completion of the sale, the insider now directly owns 24,592 shares of the company's stock, valued at $614,800. Learn More on Christine Ring's trading history.
Who are Nurix Therapeutics' active insiders?: Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), and Christine Ring (General Counsel). Learn More on Nurix Therapeutics' active insiders.
Are insiders buying or selling shares of Nurix Therapeutics?: In the last twelve months, insiders at the sold shares 23 times. They sold a total of 110,728 shares worth more than $2,215,543.67. The most recent insider tranaction occured on November, 1st when CFO Houte Hans Van sold 3,546 shares worth more than $86,096.88. Insiders at Nurix Therapeutics own 7.2% of the company. Learn More about insider trades at Nurix Therapeutics.
Information on this page was last updated on 11/1/2024.

Christine Ring Insider Trading History at Nurix Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/14/2024	Sell	3,290	$25.00	$82,250.00	24,592
10/1/2024	Sell	5,760	$22.23	$128,044.80	24,592
9/3/2024	Sell	9,050	$24.94	$225,707.00	24,592
8/26/2024	Sell	9,870	$25.01	$246,848.70	24,592
8/1/2024	Sell	5,760	$21.43	$123,436.80	24,592
7/1/2024	Sell	5,760	$20.81	$119,865.60	19,838
6/12/2024	Sell	1,900	$17.01	$32,319.00	19,838
6/5/2024	Sell	400	$17.00	$6,800.00	19,838
6/3/2024	Sell	1,596	$17.01	$27,147.96	19,838
10/31/2023	Sell	1,232	$5.20	$6,406.40	15,263
7/31/2023	Sell	1,420	$9.65	$13,703.00	12,544
5/1/2023	Sell	682	$9.88	$6,738.16	10,040
1/30/2023	Sell	848	$11.78	$9,989.44	7,261
10/31/2022	Sell	699	$12.88	$9,003.12	6,185
8/1/2022	Sell	712	$15.67	$11,157.04	4,615
5/2/2022	Sell	660	$11.75	$7,755.00	3,403
12/10/2021	Sell	1,200	$29.04	$34,848.00
10/27/2021	Sell	800	$35.25	$28,200.00
10/11/2021	Sell	1,200	$27.36	$32,832.00
9/7/2021	Sell	3,200	$35.25	$112,800.00
8/10/2021	Sell	1,200	$29.87	$35,844.00	2,005
7/20/2021	Sell	1,200	$27.00	$32,400.00
6/10/2021	Sell	1,200	$29.40	$35,280.00	2,005
5/10/2021	Sell	1,200	$27.00	$32,400.00	2,005
4/12/2021	Sell	1,200	$27.20	$32,640.00	2,005
3/10/2021	Sell	2,000	$41.27	$82,540.00

Christine Ring Buying and Selling Activity at Nurix Therapeutics

Nurix Therapeutics Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Today's Range

Now: $22.75

$22.10

$22.87

50 Day Range

MA: $24.45

$21.54

$28.14

2 Week Range

Now: $22.75

$5.65

$29.56

Volume

211,657 shs

Average Volume

903,081 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Christine Ring Biography and Net Worth

What is Christine Ring's net worth?

How old is Christine Ring?

What is Christine Ring's salary?

How do I contact Christine Ring?

Has Christine Ring been buying or selling shares of Nurix Therapeutics?

Who are Nurix Therapeutics' active insiders?

Are insiders buying or selling shares of Nurix Therapeutics?